Dynamic changes of intestinal flora in patients with irritable bowel syndrome combined with anxiety and depression after oral administration of enterobacteria capsules

Bioengineered. 2021 Dec;12(2):11885-11897. doi: 10.1080/21655979.2021.1999374.

Abstract

This study investigated the clinical characteristics and dynamic changes of intestinal bacterial community to evaluate the curative effect of fecal microbiota transplantation (FMT) on irritable bowel syndrome with predominant diarrhea (IBS-D) comorbid with anxiety and depression. Total two treatments were designed in randomize-controlled trial includes oral FMT capsules with 1 week (A1), 8 weeks (A2), and 12 weeks (A3), as well as oral empty capsules with 1 week (B1), 8 weeks (B2), and 12 weeks (B3) as control for comparison. The positive therapeutic effects occurred in FMT colonized patient with IBS-D comorbid psychological disorder, demonstrated at alleviated IBS-D severity (IBS-SSS score from 291.11 reduced to 144.44), altered stool type (from 6 changed to 4), reduced anxiety and depression scores (from 18.33 to 8.39 and from 22.33 to 17.78) after FMT-treated 12 weeks. The FMT therapy improved bacterial alpha diversity and the majority bacterial community predominant by Bacteroidetes and Firmicutes, and the relative abundance (RA) was higher after FMT-treated 12 weeks (50.61% and 45.52%) than control (47.62% and 38.96%). In short, FMT therapy has great potential for IBS-D patients combined with anxiety and depression by alleviated clinical symptoms and restore the intestinal micro-ecology.

Keywords: Diarrheal irritable bowel syndrome; anxiety and depression; bacterial community; fecal microbiota transplantation.

Publication types

  • Observational Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Anxiety / complications*
  • Bacteria / growth & development
  • Biodiversity
  • Capsules
  • Depression / complications*
  • Diarrhea / complications
  • Diarrhea / microbiology
  • Diarrhea / therapy
  • Enterobacteriaceae / physiology*
  • Fecal Microbiota Transplantation
  • Female
  • Gastrointestinal Microbiome*
  • Humans
  • Irritable Bowel Syndrome / microbiology*
  • Irritable Bowel Syndrome / psychology*
  • Irritable Bowel Syndrome / therapy
  • Male
  • Middle Aged
  • Principal Component Analysis

Substances

  • Capsules

Grants and funding

This study was supported by general project of the key research and development plan of the Science and Technology Department of Jiangxi Province (No. S2020ZPYFB0148), Fujian Province Health Research Talents Training Project (No.: 2019-1-23), Qihang Fund from Fujian Medical University (No. 2018QH1145).